Spotlight on the Mechanism of Action of Semaglutide

Spotlight on the Mechanism of Action of Semaglutide

Initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite. Integrating the latest clinical trials, semaglutide in patients with or wit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Current Issues in Molecular Biology
Subjects:	semaglutide adipose browning diabetes obesity inflammation
Online Access:	https://www.mdpi.com/1467-3045/46/12/872
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
by: Yang L, et al.
Published: (2024-11-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
by: Michela Del Prete, et al.
Published: (2025-01-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Berberine-induced browning and energy metabolism: mechanisms and implications
by: Aslıhan Alpaslan Ağaçdiken, et al.
Published: (2025-02-01)

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
by: Fernando K. Malerbi, et al.
Published: (2025-01-01)

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
by: Bea Campforts, et al.
Published: (2024-11-01)

Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India
by: Aditya Dutta, et al.
Published: (2024-12-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Carbonic anhydrase 2 mediates anti-obesity effects of black tea as thermogenic activator
by: Peng Ma, et al.
Published: (2024-09-01)

Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Diet-Induced Adipocyte Browning
by: Oskar Wojciech Wiśniewski, et al.
Published: (2021-11-01)

Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01)

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
by: Hiroya Kitsunai, et al.
Published: (2025-01-01)

Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue
by: Dihong Gong, et al.
Published: (2024-09-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Made in China: The international supply of illicit Semaglutide and weight-loss medicines online
by: Luke A. Turnock, et al.
Published: (2025-12-01)

Loss of Sult1a1 reduces body weight and increases browning of white adipose tissue
by: Margherita Springer, et al.
Published: (2024-12-01)

Senescent cell depletion alleviates obesity-related metabolic and cardiac disorders
by: Tábatha de Oliveira Silva, et al.
Published: (2025-01-01)

Sympathetic innervation of interscapular brown adipose tissue is not a predominant mediator of Oxytocin (OT)-elicited reductions of body weight gain and adiposity in male diet-induced obese rats
by: Melise M. Edwards, et al.
Published: (2024-12-01)

Wu-Mei-Wan enhances brown adipose tissue function and white adipose browning in obese mice via upregulation of HSF1
by: Shen Chen, et al.
Published: (2025-01-01)

Characteristics of T2* and anisotropy parameters in inguinal and epididymal adipose tissues after cold exposure in mice
by: Madoka Ogawa, et al.
Published: (2024-11-01)

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
by: Jakob Grauslund, et al.
Published: (2024-12-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
by: Ammar Ahmed, et al.
Published: (2024-12-01)

Obesity and reproductive health: “nocturne” to modern comorbidity
by: Mekan R. Orazov, et al.
Published: (2024-09-01)

Editorial: Insights in obesity: 2023
by: Katsunori Nonogaki
Published: (2024-11-01)

Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review
by: Khanyisani Ziqubu, et al.
Published: (2024-12-01)

Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy
by: Rajesh Yadav, et al.
Published: (2024-10-01)

Effects of Walnut Protein Peptides on Promotion of White Adipose Tissue Browning and Prevention of Obesity
by: Yankun FU, et al.
Published: (2025-02-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Maternal neonicotinoid pesticide exposure impairs glucose metabolism by deteriorating brown fat thermogenesis
by: Wenwen Zhu, et al.
Published: (2025-01-01)

Endothelial dysfunction is an early event in the pathophysiology of obesity
by: Gui-Fen ZHANG, et al.
Published: (2020-10-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health
by: Marcelo Queiroz, et al.
Published: (2024-12-01)

The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes—A Scientometric Investigation and Visualization Study
by: Ileana Pantea, et al.
Published: (2024-10-01)